December 20, 2024
FDA doubles down: Tirzepatide is off shortage
...but that doesn't mean the issue is completely settled.
December 20, 2024
Defending GLP-1 compounding
The latest letters APC's been sending to oppose efforts to restrict compounding
December 20, 2024
Thumbs-up for FDA crackdown
APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds.
December 20, 2024
A PANS/PANDAS explainer
For your patients: Information about a couple of underdiagnosed pediatric mental health conditions
December 13, 2024
Get a cease and desist letter from Verrica?
APC has heard reports from several pharmacies that have received them — here's what to know.
December 12, 2024
Morning Edition updates its GLP-1 story
NPR ran an updated story on the 'battle' between compounders and drug makers over GLP-1 weight-loss drugs.
December 12, 2024
PCF awards state association CE grants
The Pharmacy Compounding Foundation has awarded $1,500 grants to eight state pharmacy associations.
December 6, 2024
Compounding vs. counterfeit — ABC News gets it
When ABC News wanted to do a story on compounded GLP-1s, it turned to APC. Of course.
December 6, 2024
No no, Novo!
Novo Nordisk asked the FDA to put semaglutide on the Demonstrably Difficult to Compound (DDC) list, and now APC has formally responded, pulling exactly zero punches.
December 6, 2024
About that Diabetes Association statement …
The American Diabetes Association gets a good portion of its funding from pharmaceutical companies, including Eli Lilly and Novo Nordisk.
December 6, 2024
Foundation welcomes 2025 board members
Congratulations to the newest members of the Pharmacy Compounding Foundation Board of Directors
December 4, 2024
Legit or not? ABC News looks at the difference
ABC News turned to APC for insight into the difference between legit GLP-1 compounders and fly-by-night 'wellness' sites.
November 25, 2024
Covering the GLP-1 shortage
Reuters did an excellent job updating the status of the Wegovy shortage.
November 22, 2024
End Drug Shortages Act intro’d in Congress
The legislation would expand the sources the FDA may use to declare drug shortages.
November 22, 2024
FDA tirzepatide ‘reconsideration’ period extended
FDA agreed to extend until December 19 a final report on tirzepatide availability to the court.
November 22, 2024
NPR hits the GLP-1 nail on the head
A National Public Radio piece this week tackled the issue of compounded GLP-1 drugs and got the facts and nuance just right.
November 21, 2024
NPR hits the GLP-1 nail on the head
National Public Radio did a spot-on job explaining the current situation with compounded GLP-1 drugs.
November 8, 2024
APC to FDA: Just say no to Lilly
This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list.
November 8, 2024
CC: October 8, 2024
Whispering and shouting, responding to Lilly’s DDC letter, and more
November 8, 2024
California BOP sends proposed compounding regs to comment period
The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period.
November 8, 2024
Checking in on the post-Chevron fallout
What’s happened in the world of federal regulation since the end of Chevron?
November 1, 2024
PFMs can get 2.5% credit card processing
A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%.
November 1, 2024
APC election results: directors and bylaws
See the results of APC's elections, including four new directors and several changes to our bylaws.
November 1, 2024
You don’t have to miss our GLP-1 briefing
Our briefing, “What's Up with GLP-1 Compounding (And What's Next)?” is now available on demand.
November 1, 2024
PCAC votes against four nominated bulk drug substances
FDA’s Pharmacy Compounding Advisory Committee voted at a meeting Tuesday against adding four substances to the 503A bulks list.
November 1, 2024
Did someone mention glass houses?
Oopsie! The FDA has cited Novo Nordisk for “quality lapses” at one of the company’s two Ozempic manufacturing plants.
November 1, 2024
GLP-1s: Keep your patients informed
The P3 October newsletter is perfect for explaining GLP-1s to your patients.
